EP-1247: Comparison of two systems to calculate the margins for expansion from CTV to PTV in prostate cancer patients  by Pardo, J. et al.
S674                                                                                                                                         3rd ESTRO Forum 2015 
 
Sexual practices before treatment ranged from masturbation, 
oral sex, and anal sex in order of frequency, and remained 
the same after treatment. Overall sexual satisfaction 
decreased, especially for participants with urinary 
incontinence and erectile dysfunction. Many men described 
orgasms after treatment as feeling 'incomplete' due to lack of 
ejaculate. Some single men or men in open relationships 
reported a loss of confidence or difficulty meeting other men 
after treatment. More information from physicians could have 
prepared participants to better cope with side effects; 
however, participants showed resilience by continuing to 
engage in sexual activities and had a positive view of their 
life after treatment. 
Conclusions: The adverse impact of PCa treatments on 
sexual function for MSM can be a barrier to developing new 
relationships. To fulfil the principle of informed consent, 
MSM should be made aware of how PCa treatments can affect 
their sex lives. We intend to continue this research in order 
to develop a validated questionnaire to study sexual quality 
of life in MSM with prostate cancer and help guide the best 
treatment choices when MSM are diagnosed with PCa. 
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Purpose/Objective: The association of androgen deprivation 
therapy (ADT) to radiotherapy (RT) improves prognosis in 
patients with high-intermediate risk prostate cancer (PC). 
Luteinising hormone-releasing hormone (LHRH) agonists are 
the standard of care in these patients even if this treatment 
is associated with several side effects. Chronic anemia due to 
ADT with LHRH agonists is one of these. However, analyses 
focused on the impact of adyuvant ADT on chronic anemia in 
patients with PC are lacking. In particular only few studies on 
the impact of different hormonal treatments (LH-RH agonists 
vs antiandrogen) or different durations of hormone therapy 
(short-term vs. long-term) on the blood count are available. 
The purpose of this analysis is to evaluate the impact of 
adjuvant ADT on anemia. 
Materials and Methods: Data of patients with PC at 
intermediate-high risk receiving RT plus adjuvant hormone 
therapy (intermediate risk: 6 months; high risk: 24 months) 
were collected. Hemoglobin level was assessed before 
treatment and then at 2 and 5 years after radiotherapy. 
Hemoglobin mean values were calculated and these were 
compared using t-test based on type of hormone therapy 
(LHRH agonists vs antiandrogen) and duration of hormone 
therapy (6 months vs. 2 years). 
Results: One hundred eighty-six patients were evaluated. 
The results of statistical analysis are shown in the Table. 
 
 
 
Conclusions: In patients undergoing radiotherapy plus 
adjuvant hormonal therapy for PC, hemoglobin levels were 
significantly lower in the group treated with LH-RH agonists 
after 2 years. Similar values were recorded after 5 years but 
the difference was not statistically significant, probably 
because of the smaller sample size. In contrast, no difference 
was observed based on duration of adjuvant therapy. 
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Purpose/Objective: To compare two systems to calculate the 
lateral, longitudinal and vertical margins for expansion from 
CTV to PTV in prostate cancer patients. 
Materials and Methods: 29 consecutive prostate cancer 
patients treated with IMRT were included. A Cone Beam CT 
was performed the first 4 days of treatment. The average of 
the displacements regarding the reference image was 
determined and was checked by another CBCT in the fifth 
day. Subsequently a weekly CBCT test was performed 
For each patient the deviations values were obtained in the 
three directions and the average value and standard 
deviation of these errors was calculated (S>). To deal with 
random errors, the first 5 CBCT errors were corrected by 
subtracting the mean value of the systematic errors 
3rd ESTRO Forum 2015                                                                                                                                         S675 
 
corrected for each patient. With the new 'corrected' errors 
and the other errors measured during follow-up CBCT, 
standard deviation was determined for each patient. 
Then they were added quadratically, ie each individual 
overall deviation were squared, added all squares and from 
the result the standard deviation of random errors (σ) was 
obtained. Finally, for each direction, the formulas of Van 
Herk & de Stroom were applied 
Results: The mean values of the systematic errors of the first 
5 CBCT were:Sver:0,3, Slong: 0,2 y Slat: 0,2. The standard 
deviation of the random errors was: σver: 1.43, σlong: 0.77 y 
σlat: 0.96. The results of applying the formulas of van Herk 
and Stroom are shown in Table 1.  
 
 
 
 
Conclusions: No statistically significant differences were 
found between the values obtained for each of the systems 
for calculating margin expansion. Therefore, we will evaluate 
which of the two will be applied in our patients, considering 
that Stroom formula obtains a margin assuring that 99% of 
CTV is within the 95% isodose and Van Herk formula obtains a 
margin which ensures that 90% of the population receives at 
least 95% of the prescribed dose to the CTV. 
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Purpose/Objective: The application of hypofractionated 
regimen allows to reduce the treatment time of radiotherapy 
(RT) and is theoretically associated with an improvement of 
the probability of cure in patients affected by prostatic 
carcinoma (CAP). However, hypofractionated RT could be 
associated with a higher incidence of late side effects. Many 
studies are currently in progress to assess the effectiveness 
of this irradiation modality, but definitive indications about 
tolerance and efficacy of this method are still missing. The 
aim of this study was the comparison of the therapeutic 
results recorded in two different studies of CAP RT, based on 
different dose fractionation. 
Materials and Methods: In this analysis were included 
patients enrolled in: 1) an observational study on RT of 
prostate +/- seminal vesicles with 3D technique and a dose of 
73.8 Gy (1.8 Gy/fraction); 2) a phase I-II study on RT of 
prostate +/- seminal vesicles with IGRT-IMRT-SIB technique 
and a dose of 65 Gy (2.6 Gy/fraction) +/- radiosurgical boost 
(5 Gy in single fraction). Biochemical recurrence-free survival 
(according to Phoenix-criteria), local control, disease-free 
and overall survival were evaluated using the Kaplan-Meier 
method. Survival curves were compared by logrank test 
(univariate analysis) or Cox Proportional Hazard Method 
(multivariate analysis, considering as covariates: risk class, 
RT-treatment modalities, lenght of hormonal therapy). 
Patients were classified according to NCCN 2014 risk 
categories. 
Results: 326 patients have been included in this comparison. 
The results of the analysis have been reported in the table. 
Also the multivariate analysis showed no difference in terms 
of biochemical and clinical outcomes between the two groups 
of patients (p: NS). 
 
Conclusions: Comparing two prospective studies, a 
hypofractionated treatment +/- stereotactic boost showed 
comparable results in terms of toxicity and biochemical 
outcome to the standard treatment. 
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Purpose/Objective: Postoperative radiotherapy improves 
prognosis in high risk prostate cancer patients. However, 5-
year biochemical recurrence free survival does not exceed 75 
- 80%. On the basis of several randomized trials, showing a 
